Cargando…

Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer

Treatment algorithms for metastatic breast cancer describe sequential treatment with chemotherapy and, if appropriate, targeted therapy for as long as the patient receives benefit. The epothilone ixabepilone is a microtubule stabilizer approved as a monotherapy and in combination with capecitabine f...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ibrahim, Nuhad K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290913/ https://www.ncbi.nlm.nih.gov/pubmed/34295806 http://dx.doi.org/10.3389/fonc.2021.617874

Ejemplares similares

Ixabepilone development across the breast cancer continuum: a paradigm shift
por: Ibrahim, Nuhad K
Publicado: (2010)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
por: Rivera, Edgardo, et al.
Publicado: (2010)

Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
por: Egerton, Nancy
Publicado: (2010)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008)

Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
por: Cobham, Marta Vallee, et al.
Publicado: (2009)

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
por: Rak Tkaczuk, Katherine H.
Publicado: (2011)

Management of advanced breast cancer with the epothilone B analog, ixabepilone
por: Gradishar, William
Publicado: (2009)

Profile and potential of ixabepilone in the treatment of pancreatic cancer
por: Smaglo, Brandon G, et al.
Publicado: (2014)

Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients
por: Ebenezer, Gigi J, et al.
Publicado: (2014)

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer
por: Ho, Joanne, et al.
Publicado: (2009)

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells
por: Tanei, Tomonori, et al.
Publicado: (2016)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013)

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma
por: Ott, Patrick A., et al.
Publicado: (2010)

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells
por: Tam, Stanton, et al.
Publicado: (2022)

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
por: Qian, Yu, et al.
Publicado: (2022)

An Overview of Vasculogenic Mimicry in Breast Cancer
por: Andonegui-Elguera, Marco A., et al.
Publicado: (2020)

5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells
por: YAO, YONGSHAN, et al.
Publicado: (2014)

Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis
por: Wang, Changjun, et al.
Publicado: (2022)

Breast cancer: from “maximum tolerable” to “minimum effective” treatment
por: Veronesi, Umberto, et al.
Publicado: (2012)

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
por: Beumer, J. H., et al.
Publicado: (2007)

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials
por: Vahdat, Linda T., et al.
Publicado: (2012)

A systemic review of taxanes and their side effects in metastatic breast cancer
por: Lai, Jiun-I., et al.
Publicado: (2022)

Breast cancer metastatic to the kidney: Case report
por: Ahmed, Yacoub, et al.
Publicado: (2020)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
por: Haque, Emaan, et al.
Publicado: (2022)

A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy
por: Kim, Yeul Hong, et al.
Publicado: (2012)

Review of Bone Modifying Agents in Metastatic Breast Cancer
por: Raghu Subramanian, Charumathi, et al.
Publicado: (2021)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2020)

Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy
por: Kim, Jae Sik, et al.
Publicado: (2023)

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2021)

Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients
por: Tao, Zhonghua, et al.
Publicado: (2020)

Proteomic Characterization of Cytoplasmic Lipid Droplets in Human Metastatic Breast Cancer Cells
por: Zembroski, Alyssa S., et al.
Publicado: (2021)

Differences in Tumor Immune Microenvironment in Metastatic Sites of Breast Cancer
por: Lee, Hyunjong, et al.
Publicado: (2021)

Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer
por: Harry, Jordan A., et al.
Publicado: (2021)

Ureteropelvic Junction Obstruction Secondary to Metastatic Relapse of Breast Cancer
por: Shah, Paras H., et al.
Publicado: (2015)

Surgical Management of Metastatic Breast Cancer: A Mini Review
por: Ueno, Takayuki
Publicado: (2022)

ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dt54nlnqj5rt2pnbirfss4t264